Panos G Kanavos
Overview
Explore the profile of Panos G Kanavos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanavos P, Hartgers-Gubbels E, Chambers M
Int J Gen Med
. 2022 Dec;
15:8429-8435.
PMID: 36518234
How will market access and value demonstration evolve? In this episode of the Value Insider podcast, host Mike Chambers speaks with Ass. Prof. Panos Kanavos about the future of value...
2.
Gill J, Mills M, Wharton G, Kanavos P
J Cancer Policy
. 2022 Aug;
34:100352.
PMID: 35952940
To ensure the previous progress seen in cancer survival rates continues as we move through the 21st Century it is important to determine future effective policy related to oncology healthcare...
3.
Wouters O, Sandberg D, Pillay A, Kanavos P
Soc Sci Med
. 2018 Dec;
220:362-370.
PMID: 30513486
Objective: We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of...
4.
Wouters O, Kanavos P, Mckee M
Milbank Q
. 2017 Sep;
95(3):554-601.
PMID: 28895227
Context: Rising drug prices are putting pressure on health care budgets. Policymakers are assessing how they can save money through generic drugs. Methods: We compared generic drug prices and market...
5.
Wouters O, Kanavos P
BMC Health Serv Res
. 2017 Apr;
17(1):242.
PMID: 28359273
Background: Policymakers and researchers frequently compare the prices of medicines between countries. Such comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this...
6.
Wouters O, Kanavos P
Bull World Health Organ
. 2015 Oct;
93(9):606-13.
PMID: 26478624
Objective: To review the pharmaceutical sector in Cyprus in terms of the availability and affordability of medicines and to explore pharmaceutical policy options for the national health system finance reform...
7.
Wouters O, ODonoghue D, Ritchie J, Kanavos P, Narva A
Nat Rev Nephrol
. 2015 Jun;
11(8):491-502.
PMID: 26055354
Chronic kidney disease (CKD) is prevalent in many countries, and the costs associated with the care of patients with end-stage renal disease (ESRD) are estimated to exceed US$1 trillion globally....
8.
Kanavos P, Vandoros S
Health Econ Policy Law
. 2011 Jun;
6(3):337-67.
PMID: 21676345
This paper investigates the determinants of the prices of branded prescription medicines across different regulatory settings and health care systems, taking into account their launch date, patent status, market dynamics...